Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5J7F

Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.

Summary for 5J7F
Entry DOI10.2210/pdb5j7f/pdb
DescriptorE3 ubiquitin-protein ligase Mdm2, 4-({6-[(6-chloro-3-{1-[(4-chlorophenyl)methyl]-4-(4-fluorophenyl)-1H-imidazol-5-yl}-1H-indole-2-carbonyl)oxy]hexyl}amino)-4-oxobutanoic acid (3 entities in total)
Functional Keywordsp53, mdm2, mdmx, protein-protein interaction, cancer, inhibitor, ligase
Biological sourceHomo sapiens (Human)
Cellular locationNucleus, nucleoplasm: Q00987
Total number of polymer chains4
Total formula weight59354.96
Authors
Twarda-Clapa, A.,Kubica, K.,Guzik, K.,Dubin, G.,Holak, T.A. (deposition date: 2016-04-06, release date: 2017-05-17, Last modification date: 2024-01-10)
Primary citationTwarda-Clapa, A.,Krzanik, S.,Kubica, K.,Guzik, K.,Labuzek, B.,Neochoritis, C.G.,Khoury, K.,Kowalska, K.,Czub, M.,Dubin, G.,Domling, A.,Skalniak, L.,Holak, T.A.
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
J. Med. Chem., 60:4234-4244, 2017
Cited by
PubMed Abstract: The tumor suppressor protein p53, the "guardian of the genome", is inactivated in nearly all cancer types by mutations in the TP53 gene or by overexpression of its negative regulators, oncoproteins MDM2/MDMX. Recovery of p53 function by disrupting the p53-MDM2/MDMX interaction using small-molecule antagonists could provide an efficient nongenotoxic anticancer therapy. Here we present the syntheses, activities, and crystal structures of the p53-MDM2/MDMX inhibitors based on the 1,4,5-trisubstituted imidazole scaffold which are appended with aliphatic linkers that enable coupling to bioactive carriers. The compounds have favorable properties at both biochemical and cellular levels. The most effective compound 19 is a tight binder of MDM2 and activates p53 in cancer cells that express the wild-type p53, leading to cell cycle arrest and growth inhibition. Crystal structures reveal that compound 19 induces MDM2 dimerization via the aliphatic linker. This unique dimerization-binding mode opens new prospects for the optimization of the p53-MDM2/MDMX inhibitors and conjugation with bioactive carriers.
PubMed: 28482147
DOI: 10.1021/acs.jmedchem.7b00104
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon